Siegfried Group has acquired Hameln Pharma in Germany, for CHF 60 million. Hameln Pharma, consisting of Hameln Pharmaceuticals GmbH and Hameln RDS GmbH, develops and produces sterile liquid pharmaceutical products for international companies, expanding Siegfried’s sterile filling segment.
 
The Hameln Group, and its remaining subsidiaries, plans to focus on its business activities with its own brand of injectable pharmaceutical finished products. The R&D site in Slovakia will also remain in the possession of the Group.
 
The acquired companies are located in the city of Hameln and employ approximately 500 staff, which Siegfried will take over. For 2014, Hameln Pharma expects sales of approximately CHF 85 million. To supplement its core business of contract manufacturing, Hameln Pharma offers a portfolio of services ranging from product and method development to dossier compilation and registration services.
 
Hameln Pharma has a modern production plant, including a sterile facility that began operations in 2008. In the future, Siegfried plans to continue to invest in the latest technologies at both of its sites in Irvine and Hameln, as well as move forward with the production of vials in Hameln.
 
The acquisition is part of Siegfried’s Transform strategy regarding both forward and backward integration. In 2012, Siegfried acquired Alliance Medical Products, Inc. in Irvine, CA, active in a comparable market segment as Hameln Pharma, and in October 2014, operating approval was granted for the new chemical production plant for APIs in Nantong, China. Also, at its headquarters in Zofingen, Switzerland, Siegfried is currently building a chemical production plant with a capacity of 100 cubic meters, which will replace older and less efficient facilities beginning in 2015.
 
Siegfried chief executive officer Rudolf Hanko, said, “The family-owned company looks back on a history of more than 100 years and, from both a technical and a cultural point of view, represents a perfect fit with the Siegfried Group, which celebrated its 140th anniversary last year. The new location significantly supplements our activities in the field of sterile filling. Our industry is in an intensifying consolidation process. Siegfried wants to and will play an active role in this.”